Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 6/20 | 0.37 |
| ▸ | MMP2 | P08253 | 3/20 | 0.33 |
| ▸ | MMP9 | P14780 | 3/20 | 0.33 |
| ▸ | MMP8 | P22894 | 3/20 | 0.33 |
| ▸ | MMP13 | P45452 | 3/20 | 0.33 |
| ▸ | MAOA | P21397 | 3/20 | 0.33 |
| ▸ | MAOB | P27338 | 3/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24075826 | 0.87 | DGAT1 (0.35) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL22916917 | 0.83 | CYP19A1 (0.38) | DGAT1P2RX7 | |
| SCHEMBL21424270 | 0.82 | P2RX7 (0.40) | DGAT1MAOAMAOBP2RX7DDB1 | |
| SCHEMBL26719982 | 0.82 | DGAT1 (0.40) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL24075170 | 0.82 | DGAT1 (0.40) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL19153067 | 0.81 | P2RX7 (0.34) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL15932524 | 0.80 | DGAT1 (0.42) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL15932528 | 0.80 | DGAT1 (0.42) | DGAT1MMP2MMP9MMP8MMP13 | |
| SCHEMBL28025119 | 0.80 | DGAT1 (0.42) | DGAT1MAOAMAOBP2RX7DDB1 | |
| SCHEMBL27056910 | 0.79 | DGAT1 (0.41) | DGAT1MMP2MMP9MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210369873-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF TRAUMATIC BRAIN INJURY | Amydis, Inc. | 2021-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210369873-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF TRAUMATIC BRAIN INJURY | S100B, FABP7, CRYAB | DGAT1 3733/4885MMP2 873/4885MMP9 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.